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approaches to separate GVHD and GVM (eg, HDAC inhibitors
[7], proteasome inhibitors [8], JAK/STAT inhibitors [9,10], and
demethylating agents [11]) can be validated clinically.
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Accepted 9 July 2013Acute myelogenous leukemia (AML) and myelodysplastic
syndrome (MDS) are diseases that affect predominantly
older adults, and it is precisely this group of patients that
continues to suffer from particularly poor outcomes [1-4].
Although hematopoietic cell transplantation (HCT) has
emerged as an important treatment strategy for patients
with high-risk hematologic malignancies, as recently as 2
decades ago this modality was limited mainly to patients
under age 50 [5]. This arbitrary age restriction was related
primarily to concerns about early nonrelapse mortality
(NRM) and morbidity. Initial studies of HCT using myeloa-
blative conditioning regimens suggested that patients over
age 50 may experience increased toxicity from chemo-
therapy, as well as higher rates of graft-versus-host disease
(GVHD) [6]. Several factors, including improved supportive
care and the development of a decrease in intensity condi-
tioning (RIC) regimens, have led to reduced mortality after
allogeneic HCT [7]. This progress, along with the lack of
effective alternative treatment strategies for many patients,has rekindled interest in HCT for older adults with hemato-
logic malignancies and has led to an increase in the use of
HCT in these individuals [5,8-11].
Although little is known about quality of life after RIC HCT
in older patients [12], recent studies have reported some-
what promising survival results. A large database analysis of
patients age >40 undergoing RIC-HCT for AML or MDS
uncovered no adverse effect of age on NRM, disease-free
survival, or overall survival (OS) [8]. In addition, a recent
study of patients ages 60 to 70 with high-risk MDS or
secondary AML receiving RIC-HCT versus azacitidine therapy
also revealed fairly encouraging outcomes for the HCT group,
with a 2-year OS of 39%, NRM of 33%, and relapse rate of 30%
[10]. Although RIC-HCT has become an accepted strategy for
treating patients age >50, this approach is currently used in
only a relatively small proportion of older adults with AML
and MDS [13]. Moreover, while an increasing number of
studies have focused on patients age >60, few studies have
focused on patients age >70 [14].
In this issue of Biology of Blood and Marrow Trans-
plantation, Brunner et al [15] report a retrospective analysis
of 54 patients age >70 undergoing HCT at 2 afﬁliated insti-
tutions [15]. The patients had a heterogeneous group of
diseases, but more than two-thirds had AML or MDS. All
patients received an RIC regimen, mostly busuﬂan and ﬂu-
darabine, and most patients received their grafts from
matched unrelated donors. Two-year OS and progression-
free survival in the entire population were both 39%, with
reasonable rates of GVHD. Two-year OS was 53% in patients
with AML or MDS with favorable or intermediate-risk cyto-
genetics (only 1 patient had favorable cytogenetics),
compared with 30% in those with adverse cytogenetics or
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aging ﬁnding is the low overall NRM of 3.7% at day þ100 and
5.6% at 2 years post-HCT, contradicting the hypothesis that
NRM precludes HCT in older patients. The low rate of reho-
spitalization after HCT in the study population is also
a reason for optimism. In fact, similar to an earlier study of
older adults undergoing HCT, a sizeable proportion of
patients (36%) never required hospitalization after the initial
inpatient stay for transplantation [14].
Of course, as the authors themselves acknowledge, their
study is subject to all of the shortcomings that accompany
any database investigation of patients undergoing HCT. The
transplant recipient population comprised patients consid-
ered sufﬁciently robust to undergo HCT. Moreover, as should
often be the case, the vast majority of patients with AML or
MDS had received therapy before undergoing HCT, and
patients who had responded poorly to chemotherapy were
unlikely to be selected for HCT. In addition, the lack of
a control arm in the study represents a signiﬁcant limitation.
Despite the restrictions inherent to this sort of study, the
authors make a convincing case that carefully selected adults
age 70 and older can safely undergo HCT, and that HCTmerits
further exploration as a treatment option for these patients.
The authors speculatedperhaps correctlydthat because
many patients had relatively high disease risk index scores,
they would have had poor outcomes without HCT. Naturally,
however, this study does not tell us whether any of the
speciﬁc patients selected for HCT by their physicians would
have done as well or better with less aggressive therapies or
supportive care. Nevertheless, it does indicate that HCT
seems to be a sensible option for certain patients.
Even if selected older patients with AML and MDS
patients can indeed undergo HCT with reasonable survival
rates, a number of questions still remain: What conditioning
regimen(s) should be used? Which older patients should
undergo HCT? How should the general health of the patient
and also the details of the patient’s hematologic neoplasm be
taken into account?
Regarding patient selection, if some vigorous older adults
can safely undergo RIC-HCT, perhaps a subset of these older
adults are sufﬁciently ﬁt to derive further beneﬁt from more
aggressive conditioning regimens [16-18]. This issue has not
yet been fully explored. Patients with poor performance
status (ECOG 2) and those with signiﬁcant pre-
transplantation comorbidities do not appear to fare as well as
others [15,19,20]. In addition, investigators are currently
evaluating novel measures pertaining to frailty in older
patients being considered for HCT [5].
Finally, there is the challenging problem of disease-
related risk factors, which the disease risk index will help
address. It is well-known that outcomes after HCT depend in
part on the disease, as well as on the patient’s remission
status [21]. On the one hand, if older patients with AML and
MDS with favorable and intermediate cytogenetics had
better outcomes with RIC-HCT compared to those with
unfavorable cytogenetics, then one might argue that the
former had diseases more amenable to this particular
therapy. On the other hand, these better outcomes might be
related to the selection of a particularly ﬁt group of patients
with less aggressive disease, who were more likely to be in
complete remission at the time of HCT. Perhaps this group of
patients was bound to do equally well regardless of the
treatment administered. Similarly, those with unfavorable
cytogenetics were less likely to be in complete remission at
the time of HCT and perhaps were more likely to have worseoutcomes irrespective of the treatment they received. At
present, at least 2 prospective clinical trials are planned to
examine further the role of RIC-HCT in the older population
by biological assignment to HCT versus other treatment
modalities [22]. Such studies should provide insight into
which older patients are most suited for HCT.
The development of strategies to allow for alternative
sources of hematopoietic cells, including haploidentical bone
marrow and umbilical cord blood, is expanding the ability to
perform HCT in older patients. As logistical barriers to HCT in
these patients fade away, it is becoming increasingly
imperative that oncologists learn when to apply this
modality. Multiple studies show that early NRM and frequent
hospitalization do not appear to be obstacles to HCT in
relatively robust older patients. We must now turn our
attention to optimizing patient selection, as well as to
examining how quality of life is affected in older patients
undergoing allogeneic HCT.ACKNOWLEDGMENTS
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